Literature DB >> 16103146

The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.

John V Williams1, Sharon J Tollefson, Joyce E Johnson, James E Crowe.   

Abstract

Human metapneumovirus (hMPV) is a newly described paramyxovirus that is an important cause of acute respiratory tract disease. We undertook to develop a small animal model of hMPV infection, pathogenesis, and protection. Hamsters, guinea pigs, cotton rats, and nine inbred strains of mice were inoculated intranasally with hMPV. The animals were sacrificed, and nasal and lung tissue virus yields were determined by plaque titration. None of the animals exhibited respiratory symptoms. The quantity of virus present in the nasal tissue ranged from 4.6 x 10(2) PFU/gram tissue (C3H mice) to greater than 10(5) PFU/gram (hamster). The amount of virus in the lungs was considerably less than in nasal tissue in each species tested, ranging from undetectable (<5 PFU/g; guinea pigs) to 1.8 x 10(5) PFU/gram (cotton rat). The peak virus titer in cotton rat lungs occurred on day 4 postinfection. hMPV-infected cotton rat lungs examined on day 4 postinfection exhibited histopathological changes consisting of peribronchial inflammatory infiltrates. Immunohistochemical staining detected virus only at the luminal surfaces of respiratory epithelial cells throughout the respiratory tract. hMPV-infected cotton rats mounted virus-neutralizing antibody responses and were partially protected against virus shedding and lung pathology on subsequent rechallenge with hMPV. Viral antigen was undetectable in the lungs on challenge of previously infected animals. This study demonstrates that the cotton rat is a permissive small animal model of hMPV infection that exhibits lung histopathology associated with infection and that primary infection protected animals against subsequent infection. This model will allow further in vivo studies of hMPV pathogenesis and evaluation of vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103146      PMCID: PMC1193579          DOI: 10.1128/JVI.79.17.10944-10951.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice.

Authors:  Rene Alvarez; Ralph A Tripp
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Outbreak of human metapneumovirus infection in norwegian children.

Authors:  Henrik Døllner; Kari Risnes; Andreas Radtke; Svein Arne Nordbø
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

3.  Sequence polymorphism of the predicted human metapneumovirus G glycoprotein.

Authors:  Teresa C T Peret; Yacine Abed; Larry J Anderson; Dean D Erdman; Guy Boivin
Journal:  J Gen Virol       Date:  2004-03       Impact factor: 3.891

4.  Human metapneumovirus infection in Japanese children.

Authors:  Takashi Ebihara; Rika Endo; Hideaki Kikuta; Nobuhisa Ishiguro; Hiroaki Ishiko; Michimaru Hara; Yutaka Takahashi; Kunihiko Kobayashi
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

5.  Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.

Authors:  John V Williams; Paul A Harris; Sharon J Tollefson; Lisa L Halburnt-Rush; Joyce M Pingsterhaus; Kathryn M Edwards; Peter F Wright; James E Crowe
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

6.  Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients.

Authors:  Bernadette G van den Hoogen; Gerard J J van Doornum; John C Fockens; Jan J Cornelissen; Walter E P Beyer; Ronald de Groot; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Infect Dis       Date:  2003-10-27       Impact factor: 5.226

7.  Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design.

Authors:  Mia MacPhail; Jeanne H Schickli; Roderick S Tang; Jasmine Kaur; Christopher Robinson; Ron A M Fouchier; Albert D M E Osterhaus; Richard R Spaete; Aurelia A Haller
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

8.  Human metapneumovirus-associated atypical pneumonia and SARS.

Authors:  Paul K S Chan; Ka-Fai To; Alan Wu; Gary M K Tse; Kui-Fat Chan; Siu-Fai Lui; Joseph J Y Sung; John S Tam; Brian Tomlinson
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

9.  Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract.

Authors:  Thijs Kuiken; Bernadette G van den Hoogen; Debby A J van Riel; Jon D Laman; Geert van Amerongen; Leo Sprong; Ron A M Fouchier; Albert D M E Osterhaus
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

10.  A 1-year experience with human metapneumovirus in children aged <5 years.

Authors:  Frank Esper; Richard A Martinello; Derek Boucher; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2004-04-02       Impact factor: 5.226

View more
  58 in total

1.  Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.

Authors:  Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Acute Viral Respiratory Infection Rapidly Induces a CD8+ T Cell Exhaustion-like Phenotype.

Authors:  John J Erickson; Pengcheng Lu; Sherry Wen; Andrew K Hastings; Pavlo Gilchuk; Sebastian Joyce; Yu Shyr; John V Williams
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

3.  Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection.

Authors:  Marie-Eve Hamelin; Gregory A Prince; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.

Authors:  Andrew K Hastings; Pavlo Gilchuk; Sebastian Joyce; John V Williams
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

5.  Modeling Human Respiratory Viral Infections in the Cotton Rat (Sigmodon hispidus).

Authors:  Jorge Cg Blanco; Marina S Boukhvalova; Daniel R Perez; Stefanie N Vogel; Adriana Kajon
Journal:  J Antivir Antiretrovir       Date:  2014-03-03

Review 6.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

7.  T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection.

Authors:  Deepthi Kolli; Efthalia L Bataki; Leanne Spetch; Antonieta Guerrero-Plata; Alan M Jewell; Pedro A Piedra; Gregg N Milligan; Roberto P Garofalo; Antonella Casola
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Acute clearance of human metapneumovirus occurs independently of natural killer cells.

Authors:  Sherry C Wen; Sharon J Tollefson; Monika Johnson; Pavlo Gilchuk; Kelli L Boyd; Bryan Shepherd; Sebastian Joyce; John V Williams
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

9.  An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.

Authors:  Hoyin Mok; Sharon J Tollefson; Amy B Podsiad; Bryan E Shepherd; Vasiliy V Polosukhin; Robert E Johnston; John V Williams; James E Crowe
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Human metapneumovirus small hydrophobic (SH) protein downregulates type I IFN pathway signaling by affecting STAT1 expression and phosphorylation.

Authors:  Andrew K Hastings; Katherine R Amato; Sherry C Wen; Laura S Peterson; John V Williams
Journal:  Virology       Date:  2016-04-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.